论文部分内容阅读
50年代以来,评价红细胞抗体临床意义的两种主要方法均与抗体的体外血清学特性和/或~(51)Cr标记红细胞存活研究有关。然而大量资料表明体外血清学特征并不能帮助我们预测很多抗体的临床意义。直至80年代,在应用体外细胞测定法时,预测同种抗体临床意义的唯一可靠的方法仍是进行~(51)Cr红细胞存活研究。但是对大多数医院(甚至大医院)进行~(51)Cr标记的红细胞“相容性”研究都是困难的。因此,当有人怀疑抗体致敏的红细胞在体内网状内皮系统(RES)内被巨噬细胞破坏时,便采用体外巨噬细胞/单核细胞模型进行实验,到80年代,该模型才用于预测红细胞同种抗体的临床意义。
Since the 1950s, the two main methods for evaluating the clinical significance of erythrocytic antibodies are related to the in vitro serological characteristics of antibodies and / or the study of ~ (51) Cr-labeled erythrocyte survival. However, a large number of data indicate that in vitro serological characteristics and can not help us predict the clinical significance of many antibodies. Until the 1980s, the only reliable method for predicting the clinical significance of alloantibodies was to study the survival of ~ (51) Cr erythrocytes when in vitro cytometry was used. However, it is difficult to study the “51Cr-labeled erythrocyte” compatibility in most hospitals (even in large hospitals). Therefore, when it is suspected that antibody-sensitized erythrocytes are destroyed by macrophages in the reticuloendothelial system (RES) in vivo, an in vitro macrophage / monocyte model was used for experiments and was only used in the 1980’s Clinical significance of predicting erythrocyte alloantibodies.